Quick Answer
The first month is mostly process rather than results: a consultation and a baseline lab panel, a prescription sent to a licensed 503A compounding pharmacy, medication arriving with instruction on how to store and administer it, and a follow-up at around four weeks where labs and symptoms are reviewed together. Sleep quality is what patients most often report changing early; body composition works on a much longer clock, and a month is not long enough to judge it.
There is a lot of material online about whether peptide therapy is worth doing and almost none about what actually happens once you say yes. This is that article. It describes process, not dosing — dosing is set by a physician for an individual patient, and no article should be giving you numbers to follow.
Everything here describes physician-directed care at Vitality Texas. If you have not got as far as deciding, the prior question is answered in am I a candidate for peptide therapy.
Before Day One: Consultation and Labs
Nothing is prescribed from a questionnaire. The first appointment is a conversation about symptoms, history, medications, training and sleep, followed by a blood draw. The panel is built around what is actually being asked: IGF-1 as the baseline for the growth hormone axis, a metabolic panel including fasting glucose, thyroid function, a complete blood count, and hormone markers where the clinical picture calls for them. Bloodwork is drawn on-site and results come back the following day.
What Dr. Jaqua is deciding from that is not only “which peptide”. It is whether a peptide is the right answer at all. Fatigue, poor sleep and stalled body composition are shared by low testosterone, thyroid disease, sleep apnea, anemia, depression and simple sleep deprivation, and a proportion of people who come in asking about peptides leave with a different investigation instead. That is a feature of the evaluation rather than a failure of it.
If a protocol is appropriate, this is also the point at which contraindications get ruled out and, for anyone in tested competition, anti-doping status gets raised — growth hormone secretagogues are on the World Anti-Doping Agency Prohibited List.
Week One: The Pharmacy, the Vial and the First Injection
Peptide prescriptions are dispensed by a licensed 503A compounding pharmacy, which prepares medication for a named patient against a specific prescription. That is the legal route for this class of medicine in the United States and it is the reason the process has more steps than an online order. Turnaround is typically a few days rather than same-day.
Medication generally arrives as a small vial, often refrigerated, with syringes. Depending on the preparation it may need reconstituting before first use. You are shown how to handle, store and administer it — including injection-site rotation and what to do with sharps — before you do it for the first time, and the clinic is reachable if something about the first dose is unclear.
Sermorelin and CJC-1295 + Ipamorelin are given subcutaneously, usually in the evening, because the growth hormone axis is at its most active during sleep. The mechanism behind that timing is covered on the sermorelin page.
Weeks Two and Three: What Is Real and What Is Too Early
The most commonly reported early change is sleep — deeper sleep, fewer wakings, feeling more restored in the morning. That report has a plausible mechanism behind it rather than being pure expectation: growth hormone secretion in humans is tightly coupled to slow-wave sleep, and the relationship runs in both directions.1 In controlled human work, growth hormone-releasing hormone administration increased slow-wave sleep, and it did so more effectively when given in pulses than continuously.2
Two honest caveats belong with that. First, those studies examined GHRH administration under research conditions, not months of compounded secretagogue therapy in a clinic, so the mechanism is supported and the clinical outcome is not established by trial. Second, early sleep improvement is commonly reported and individually variable — some patients notice nothing in the first month, and that is within the normal range rather than a sign the protocol has failed.
What is definitely too early is body composition. The published trials of growth hormone in healthy older adults ran for a mean of around six months and still produced only modest changes in lean and fat mass.3A secretagogue works upstream of that, through the patient's own pituitary, so the timeline is not shorter. Anyone reporting dramatic body recomposition at three weeks is describing something other than the drug.
Side Effects in the First Month
The effects that show up early are mostly minor and mostly manageable:
- Injection-site reactions — redness, itching or a small lump, usually settling within a day and reduced by rotating sites.
- Fluid retention, sometimes noticed as puffiness in the hands or ankles. Soft-tissue edema is among the effects reported more often with growth hormone than with placebo.3
- Joint discomfort or transient tingling in the hands. Arthralgia and carpal tunnel symptoms are recognised growth hormone-associated effects and are a reason to contact the clinic rather than to push through.3
- Appetite changes. Ipamorelin acts at the ghrelin receptor, and increased hunger is a recognised class effect of growth hormone-releasing peptides.4
- Changes in glucose handling. Growth hormone opposes insulin, and glucose intolerance was reported more often in treated participants in the healthy-elderly review.3 This is watched on labs rather than by symptom.
The fuller picture, including the rarer effects, is in peptide therapy side effects, and there is no point duplicating it here.
Week Four: The Follow-Up
The first review is where the month gets interpreted. Symptoms are taken alongside repeat labs — IGF-1 to see whether the axis has responded at all, glucose handling, and anything the baseline panel flagged. Adherence gets an honest airing too: a protocol taken four nights a week is a different protocol, and it is more useful to say so than to have the dose adjusted against a picture that is not real.
From that, one of four things happens: continue unchanged, adjust, investigate something the labs turned up, or stop. Dr. Jaqua would stop or change a protocol for a lab moving in the wrong direction, a side effect that is not settling, a new diagnosis that changes the risk picture, or an IGF-1 that has not moved in a patient who is taking it as prescribed.
What the First Month Does Not Tell You
It does not tell you whether the therapy has worked. It tells you whether you tolerate it, whether the axis responds, and whether the practical side of it fits your life. Those are worth knowing and they are not the same question. Patients who expect a verdict at thirty days tend to quit at the point where the evidence base says the useful data has not arrived yet.
Cost is the other thing worth settling early rather than late — what drives it is set out in how much does peptide therapy cost.
Frequently Asked Questions
How soon will I notice anything?
Sleep quality is the change patients most often report first, sometimes within the first week or two, and there is a mechanistic reason for it: growth hormone secretion is concentrated in slow-wave sleep and growth hormone-releasing hormone administration increases slow-wave sleep in human studies. That said, early sleep reports are individual and are not established as an outcome of secretagogue therapy by trial. Changes in body composition run on a much longer clock — the trials of growth hormone in healthy older adults ran for months, not weeks.
Do I inject myself?
In most protocols, yes — these are small subcutaneous injections a patient gives themselves at home. You are shown how before you do it, including site rotation, handling and storage, and nobody is sent away with a vial and a leaflet. If self-injection is something you know you will not manage, say so at consultation, because it changes what is worth prescribing.
What if I miss a dose?
Contact the clinic rather than improvising. The right response depends on the protocol and on how much time has passed, and it is a question for the prescriber, not something to be worked out from a forum. What you should not do is take extra to make up for it.
How often are labs repeated?
There is a baseline panel before anything is prescribed and a re-check after the protocol has been running long enough to have moved something — commonly around the first follow-up and then at a settled interval. IGF-1 is the marker that tells Dr. Jaqua whether the peptide is doing anything, and glucose handling is watched alongside it because growth hormone opposes insulin.
Can I stop after a month?
Yes. This is prescription therapy, not a contract, and stopping is a conversation with your physician rather than a cancellation form. It is worth knowing that a month is a short window in which to judge most of what peptide therapy is prescribed for, so stopping at four weeks usually means stopping before the question has been answered.
How much does the first month cost?
Cost depends on the peptide, the dosing schedule and the duration of the program, and it is reviewed in full at consultation rather than published as a headline figure. Our article on what drives peptide therapy pricing explains the components — medication, compounding, labs and physician follow-up — so you can see what you are being quoted for.
References
- Van Cauter E, Plat L, Copinschi G. “Interrelations Between Sleep and the Somatotropic Axis.” Sleep. 1998;21(6):553–566. DOI: 10.1093/sleep/21.6.553
- Marshall L, Mölle M, Böschen G, Steiger A, Fehm HL, Born J. “Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS).” J Clin Endocrinol Metab. 1996;81(3):1009–1013. DOI: 10.1210/jcem.81.3.8772566
- Liu H, Bravata DM, Olkin I, et al. “Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly.” Ann Intern Med. 2007;146(2):104–115. DOI: 10.7326/0003-4819-146-2-200701160-00005
- Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev. 2018;6(1):45–53. DOI: 10.1016/j.sxmr.2017.02.004
This article is general information and is not medical advice, and it deliberately contains no dosing instructions. Peptide protocols are prescribed off-label at physician discretion following individual evaluation and have not received drug approval from the FDA for the uses described.